Page 5 - Pharma Sctors
Tabreed to invest $200 mn in Telangana to develop district cooling plants
Tabreed, a UAE-based global leader in cooling utilities, on Wednesday said it has partnered with Telangana government to develop cooling infrastructure for industrial and commercial parks, and will invest USD 200 million to develop 1,25,000 RT (refrigeration tonne) of district cooling plants for Hyderabad Pharma City. The state government also signed a MoU with Tabreed to explore district cooling infrastructure in existing and upcoming commercial districts of Cyberabad near here and other mixed use development areas. Speaking on the occasion, Telangana Urban Development, Industries and Commerce Minister K T Rama Rao said, "As we embark on a journey towards a more sustainable future, we are delighted to partner with Tabreed, exemplifying Government of Telangana's commitment to environmental stewardship through embracing innovative and implementable solutions." Tabreed chairman Khaled Abdulla Al Qubaisi said,"By bringing our expertise in district cooling to the world's largest net zer
 "Tabreed to invest $200 mn in Telangana to develop district cooling plants")
Cipla, Glenmark: Time to accumulate pharma stocks on robust bullish trend?
The current volatility in the benchmark indices offer the ideal opportunity to accumulate pharma stocks around their respective supports
 "Cipla, Glenmark: Time to accumulate pharma stocks on robust bullish trend?")
A critical lapse in Jan Vishwas Bill
In seeking to make life easier for entrepreneurs, the proposed new law raises several questions on patient safety
 "A critical lapse in Jan Vishwas Bill")
Nirma looks to raise up to Rs 7,000 crore to fund buys and expansion
The unlisted company posted revenues to the tune of Rs 11,403 crore in fiscal 2023
 "Nirma looks to raise up to Rs 7,000 crore to fund buys and expansion")
Waiver for rare disease drugs brings little relief: Pharma sector
Industry bats for extending exemption to drugs that are already commercially available in India
 "Waiver for rare disease drugs brings little relief: Pharma sector")
Schedule M of Drugs and Cosmetics Act to be made must for all pharma units
Govt wants units to move towards GMP through self regulation
Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks
Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers
 "Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks")
'4IR': The booster pharma majors are taking to improve productivity
Large manufacturers are leveraging new-age technologies and advanced analytics to improve productivity and reduce deviations in production processes
Divis Lab, Sun Pharma: Current breakout may lead Pharma index to new peak
Pharm index has broken out on upside, with the positive rally anticipated to hit 14,450
 "Divis Lab, Sun Pharma: Current breakout may lead Pharma index to new peak")
Lupin likely to demerge its active pharmaceutical ingredients business
As such the API business contributes around 7 percent to Lupin's overall turnover
 "Lupin likely to demerge its active pharmaceutical ingredients business")
Self-regulatory body for pharma industry on cards: Mansukh Mandaviya
Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants
 "Self-regulatory body for pharma industry on cards: Mansukh Mandaviya")
Fewer Indian pharma plants get US FDA action notice in 2023, so far
6 per cent of inspections in first 6 months of CY23 resulted in OAI status
Lupin signs MoU with Maharashtra govt to combat rising prevalence of CVD
Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services
 "Lupin signs MoU with Maharashtra govt to combat rising prevalence of CVD")
Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data
Focus on profitability, and less options other reasons behind the slowdown seen till May this year
 "Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data")
USFDA inspections of Indian sites still below pre-Covid-19 levels
On an average Indian sites have had only a 9% share of total global inspections, analysts point out
 "USFDA inspections of Indian sites still below pre-Covid-19 levels")
India's contribution to global clinical trials at 4% during 2010-22: Study
Trials sponsored by top 20 pharma companies increased 10% since 2013
 "India's contribution to global clinical trials at 4% during 2010-22: Study")
Online pharmacies suffer without regulatory prescriptions in India
The absence of a legal framework governing this fast-growing segment of the pharma retailing business is causing confusion in the industry
 "Online pharmacies suffer without regulatory prescriptions in India")
Indian pharma R&D spends stay stagnant three years after pandemic downturn
Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US
 "Indian pharma R&D spends stay stagnant three years after pandemic downturn")
Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins
Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady
 "Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins")
Pharma firms with India focus preferred as US market concerns grow
Steady outlook and higher returns triggers for companies refining their strategy
 "Pharma firms with India focus preferred as US market concerns grow")